Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
PM R ; 2024 Oct 22.
Artículo en Inglés | MEDLINE | ID: mdl-39436090

RESUMEN

BACKGROUND: Botulinum toxin injections are well established and commonly used for spasticity management. Clinicians strive to optimize outcomes from toxin injections. One potential complication is toxin spread beyond the intended muscle, which can lead to unwanted weakness. The utilization of ultrasound allows direct visualization of target muscles and identification of toxin leakage from the target muscle. Ultrasound evaluation of clinical factors that correlate to toxin leakage have not been studied. OBJECTIVE: To identify cases of botulinum toxin injectate leak beyond the targeted muscle during ultrasound-guided spasticity injections and associate cases of leak with predictive clinical factors, which include muscle size, fibroadipose changes, and number of previous injections. DESIGN: This was a prospective observational study. SETTING: An outpatient clinic in an academic medical center. PATIENTS: Patients who demonstrated wrist flexor spasticity warranting intervention were invited to participate. INTERVENTIONS: Patients received standard-of-care spasticity management with injection of onabotulinumtoxinA into the flexor carpi radialis muscle based upon clinical presentation and prescribing guidelines. Ultrasound video was recorded, and a blinded review was conducted by the study team. MAIN OUTCOME MEASURES: The primary outcome measure was visualized leak of injectate on recorded ultrasound video. Documented leak was then associated with clinical factors including diameter of the flexor carpi radialis, volume of injectate used, history of prior injections, and fibrotic change of the muscle. OUTCOMES: The study included 54 patients, 77.8% of whom had an underlying diagnosis of cerebrovascular accident. Injectate leak was observed in 18.5% of injections and could not be confirmed in 9.3% of injections. Multivariable analysis demonstrated increased odds of leak with higher Modified Heckmatt Scale score. No statistically significant increase in leak was noted with higher volume of injectate or smaller muscle diameter. CONCLUSION: Extramuscular leak of botulinum toxin injection may be associated with fibroadipose muscle change.

2.
J Rehabil Med ; 53(1): jrm00134, 2021 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-33057730

RESUMEN

This consensus paper is derived from a meeting of an international group of 19 neurological rehabilitation specialists with a combined experience of more than 250 years (range 4-25 years; mean 14.1 years) in treating post-stroke spasticity with botulinum toxin A. The group undertook critical assessments of some recurring practical challenges, not yet addressed in guidelines, through an exten-sive literature search. They then discussed the results in the light of their individual clinical experience and developed consensus statements to present to the wider community who treat such patients. The analysis provides a comprehensive overview of treatment with botulinum toxin A, including the use of adjunctive therapies, within a multidisciplinary context, and is aimed at practicing clinicians who treat patients with post-stroke spasticity and require further practical guidance on the use of botulinum toxin A. This paper does not replicate information published elsewhere, but instead aims to provide practical advice to help optimize the use of botulinum toxin A and maximize clinical outcomes. The recommendations for each topic are summarized in a series of statements. Where published high-quality evidence exists, the recommendations reflect this. However, where evidence is not yet conclusive, the group members issued statements and, in some cas-es, made recommendations based on their clinical experience.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Espasticidad Muscular/tratamiento farmacológico , Accidente Cerebrovascular/complicaciones , Consenso , Humanos , Fármacos Neuromusculares/uso terapéutico
3.
Phys Med Rehabil Clin N Am ; 29(3): 519-527, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-30626512

RESUMEN

The key to the successful treatment of patients with spasticity is contingent on choosing appropriate interventions tailored to meet the needs, goals, and specific presentation of each patient. For the clinician attempting to address the focal manifestations of hypertonia without surgical intervention, there have been 2 primary options: neurolysis or chemodenervation. Before the introduction of the botulinum toxins, neurolysis was the only focal spasticity treatment option available to the previous generation of physical medicine and rehabilitation practitioners.


Asunto(s)
Hipertonía Muscular/terapia , Bloqueo Nervioso , Anciano , Humanos , Masculino , Persona de Mediana Edad , Bloqueo Nervioso/efectos adversos , Bloqueo Nervioso/métodos
4.
Am J Phys Med Rehabil ; 91(3): 243-53, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22173081

RESUMEN

This project endeavored to create an educational module including methodology to instruct physical medicine and rehabilitation residents in the evaluation and appropriate treatment of patients with spasticity and other sequelae of the upper motor neuron syndrome. It further sought to verify acquired competencies in spasticity management through objective evaluation methodology. A physical medicine and rehabilitation board-certified physician with 10 yrs clinical experience in spasticity management trained 16 residents using a standardized competency-based module. Assessment tools developed for this program address the basic competencies outlined by the Accreditation Council for Graduate Medical Education. The 16 residents successfully demonstrated proficiency in every segment of the evaluation module by the end of the Postgraduate Year 3 spasticity management rotation. Objective measures compared resident scores on an institution-specific standardized test administered before and after training. Resident proficiency in the skills and knowledge pertaining to spasticity management was objectively verified after completion of the standardized educational module. Validation of the assessment tool is evidenced by significantly improved postrotational institution-specific standardized test scores (mean pretest score, 61.1%; mean posttest score, 95.4%) as well as oral testing. In addition, the clinical development tool was validated by residents being individually observed performing skills and deemed competent by a board-certified physical medicine and rehabilitation physician specializing in spasticity management. The standardized educational module and evaluation methodology provide a potential framework for the definition of baseline competency in the clinical skill area of spasticity management.


Asunto(s)
Competencia Clínica , Evaluación Educacional/métodos , Internado y Residencia , Espasticidad Muscular/terapia , Medicina Física y Rehabilitación/educación , Baclofeno/administración & dosificación , Toxinas Botulínicas/administración & dosificación , Curriculum , Documentación , Trastornos Neurológicos de la Marcha/diagnóstico , Trastornos Neurológicos de la Marcha/terapia , Humanos , Inyecciones Espinales , Relajantes Musculares Centrales/administración & dosificación , Bloqueo Nervioso , New Jersey , Satisfacción del Paciente , Examen Físico , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...